Fundraising FoxOno Venture Investment, Inc.
Corporate VCSouth San Francisco · Seed–Series B · 6 people tracked
Find your way into Ono Venture Investment, Inc.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Shiho Hirose to introduce you to Kousuke Tani
You →Shiho · together at ONO PHARMACEUTICAL CO., LTD. →Kousuke
Ask Jamie Chen to introduce you to Haruhito Tsutsui
You →Jamie · together at Alchemab →Haruhito
Ask Sam Okafor to introduce you to Daisuke Nakayama
You →Sam · together at Ono Pharmaceutical Co., Ltd. →Daisuke
- Ryohei Miyata1 person can intro you
Sign up to find every way you can get introduced to Ono Venture Investment, Inc.
- Your email: who you already know at Ono Venture Investment, Inc., and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Ono Venture Investment, Inc. team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Ono Venture Investment invests in early-stage startups to access innovative technologies and novel therapeutic drug targets, emphasizing collaboration with young companies. Its activity centers on the life sciences and biotech space, backing therapeutics developers and related platforms, and it participates in follow-on rounds to support portfolio companies as they advance.
Source: firm website, verified Sep 27, 2026.
Team · 6 people
from the firm's website & public directories
What they invest in
from 16 of 17 portfolio companiesBiotech ×12Healthtech ×7Deep Tech ×6Medical Devices ×5Digital Health ×4AI & Machine Learning ×3Data & Infrastructure ×2B2B Marketplaces ×1
HQs:United States×11Australia×1
Investments · 17 tracked
founders shown can be your intro pathBy year:2023 · 62021 · 39 dated
Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets.
BiotechHealthtech
Jan Thirkettle(CEO Director)in
Co-investorsEpidarex CapitalDementia Discovery FundSV Health Investors
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Chief Executive Officer)
Co-investorsRA CapitalSV Health InvestorsDCVC BioDementia Discovery FundLightstone VenturesBritish Business Bank+2 more
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)David Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)
Co-investorsARCH Venture PartnersIllumina VenturesTCG CrossoverAlly Bridge GroupJanus Henderson InvestorsRevelation Partners+4 more
Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications.
BiotechDeep TechHealthtechBoston, US
Andrea Ballabio(Founder)Beth Levine(Founder)Herbert Virgin(Founder)James Hurley(Founder)in
Co-investorsAstellas Venture Management LLCThird Rock VenturesEisai Innovation, Inc.The Column Group
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Co-investorsAgent CapitalDC Investment PartnersLongwood FundMedical Excellence CapitalNovartis Venture FundSolasta Ventures+3 more
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Co-investorsAgent CapitalGimvLongwood FundMission BiocapitalNovartis Venture FundPfizer Venture Investments+4 more
Mission BioCapital is a venture capital firm that invests in early-stage life science companies, from therapeutics and drug discovery to biotech tools and diagnostics.
BiotechDeep TechSan Francisco, US
BoardDouglas Crawford, PhD(Managing General Partner)Peter Parker(Managing General Partner)
Co-investorsConnecticut Innovations
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in
Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundPfizer Venture InvestmentsSofinnova PartnersAlexandria+4 more
Photys Therapeutics develops bifunctional small-molecule medicines that use induced proximity to recruit kinases and drive targeted protein phosphorylation, aiming to modulate and repair disease-driving proteins.
BiotechHealthtechLongevityWaltham, US
Amit Choudhary(Scientific Founder)David Steinberg(Chairman & Founding CEO)inEdward Holson(Co-founder & CSO)inLizzie Ngo(Co-founder)inBrian Fenton(President & CEO)in
Co-investorsLongwood FundMPM BioImpact8VCMRL Ventures Fund
Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Si-Ping Han(Secretary)inDeepshikha Datta(Chief Executive Officer and President)
BoardKevin Zhang(Director)Alicia Irurzun-Lafitte(Director)inDylan Morris(Director)in
Co-investorsBold Capital PartnersCRV (Charles River Ventures)Dolby Family VenturesFREEFLOWGlobal BrainUpfront Ventures+2 more
Violet Labs builds software tools for engineers designing and building physical products across industries including aerospace, defense, robotics, and energy.
Data & InfrastructureDeveloper ToolsEnterprise SoftwareHardware
Lucy Hoag(Founder)in
Co-investorsFelicis VenturesMaC Venture CapitalMairs & Power VCV1 VCDementia Discovery FundHopelab+4 more
Violet provides free, personalised support for Australian families navigating end-of-life care, combining human connection and technology to offer practical guidance, emotional support, and tools for important conversations.
Digital HealthFintechHealthtechImpact & Social GoodMental HealthHaymarket, AU
BoardKate Carnell(Chairperson)
Co-investorsTechstarsDementia Discovery FundHopelabNorthwell HoldingsSemperVirens Venture CapitalThe Venture Collective+1 more
Violet provides healthcare organizations with data analytics and tools to measure and improve their ability to deliver person-centered care that considers patients' individual preferences, identities, and experiences.
Data & InfrastructureDigital HealthHealthtechNew York City, US
Gaurang Choksi(CEO and Founder)inScott Zaloom(Head of Operations)inDr. Kay Nikiforova(Head of Clinical & Research)inEliot Kristan(Head of Engineering)in
Co-investorsSeae VenturesSemperVirens Venture CapitalThe Venture CollectiveW Health Ventures Gp LlcDementia Discovery FundHopelab+2 more
Violet provides a unified API for commerce infrastructure that simplifies checkout, catalog management, and order processing for platforms and marketplaces serving multiple merchants.
B2B MarketplacesE-commerceSaaSSeattle, US
Brandon Schulz(Founder)inRhen Zabel(Executive Officer, Director, Promoter)Adam Dreiblatt(Director)
Co-investorsAlumni VenturesSeaChangeDementia Discovery FundHopelabNorthwell HoldingsRed Sea Ventures+4 more
Violet is a therapeutics company developing small molecule treatments for central nervous system diseases, using its proprietary C-to-C Engine platform to identify disease-relevant cell-to-cell interactions.
BiotechDeep TechCambridge, US
Co-investorsDementia DiscoveryDementia Discovery FundSV Health InvestorsUTEC
AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.
AI & Machine LearningBiotechDeep TechHealthtechStanford, US
Thorsten Stafforst(Chairman of the Board of Directors)inKris ElveruminTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in
BoardRodger Novak(Chair)in
Co-investors+ND CapitalARCH Venture PartnersForbionVenrockFast Track InitiativeNextech Invest+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Arclight Therapeutics LLC
Portfolio news
latest coverage across their companiesAlchemab · trysignalbase.com · Jul 10, 2026
Frequently asked questions
- How many investments has Ono Venture Investment, Inc. made?
- Ono Venture Investment, Inc. has 17 tracked investments.
- What stage does Ono Venture Investment, Inc. invest at?
- Ono Venture Investment, Inc. invests at the Seed, Series A, Series B stages.
- What sectors does Ono Venture Investment, Inc. focus on?
- Ono Venture Investment, Inc. focuses on Biotech, Healthtech.
- Where is Ono Venture Investment, Inc. located?
- Ono Venture Investment, Inc. is headquartered in South San Francisco, US.
- Who does Ono Venture Investment, Inc. co-invest with?
- Ono Venture Investment, Inc. most often shares deals with ARCH Venture Partners, Longwood Fund, Agent Capital, among 38 tracked co-investors.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.